Nomelcitinib tops Phase 3 endpoints in plaque psoriasis
InventisBio’s nomelcitinib met PASI-90 and PGA 0/1 endpoints in a 391-patient Phase 3 psoriasis trial, with more than 70% and 80% responding at Week 16.
Topic
Nomelcitinib
Topic
Topic
Topic
InventisBio’s nomelcitinib met PASI-90 and PGA 0/1 endpoints in a 391-patient Phase 3 psoriasis trial, with more than 70% and 80% responding at Week 16.